PHIO vs TROW · $10.4M cap vs P/E 12, rev $7.09B
Phio Pharmaceuticals Corp (PHIO) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Phio Pharmaceuticals Corp (PHIO) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
PHIO does not have a complete income-statement cache yet.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
PHIO currently screens at market cap $10.4M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the PHIO and TROW stock pages for the full models.
Not investment advice.